Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer

Journal of Urology

Volumn 163, Issue 4, 2000, Pages 1085-1089

  Critz, Frank A ^a   Williams, W Hamilton ^a   Benton, James B ^a   Levinson, A Keith ^a   Holladay, Clinton T ^a   Holladay, David A ^a  

^a Radiother Clinics Georgia G   (United States)

Author keywords

Brachytherapy; Prostate; Prostate specific antigen; Prostatic neoplasms; Radiotherapy

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

EID: 0034066942     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67698-7     Document Type: Article

References (6)

1. Critz, F. A., Levinson, A. K., Williams, W. H., et al: Posttreatment PSA ≤ 0.2 ng./ml. defines disease-freedom after radiotherapy of prostate cancer with modern techniques. Urology, 54: 968, 1999
2. Hanks, G. E., Hanlon, A. L., Schultheiss, T. E., et al: Conformal external beam treatment of prostate cancer. Urology, 50: 87, 1997
3. Wallner, K., Roy, J. and Harrison, L.: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol, 14: 449, 1996
4. Beyer, D. C. and Priestley, J. B., Jr.: Biochemical disease-free survival following 1251 prostate implantation. Int J Radiat Oncol, 37: 559, 1997
5. American Society for Therapeutic Radiology and Oncology Con-sensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol, 37: 1035, 1997
6. Crook, J. M., Perry, G. A., Robertson, S. et al: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology, 45: 624, 1995